tecovirimat + sucroferric oxyhydroxide

Tecovirimat + sucroferric oxyhydroxide is a hypothetical combination drug containing both **tecovirimat** and **sucroferric oxyhydroxide**. - **Tecovirimat** is an antiviral small molecule that inhibits orthopoxvirus replication (including smallpox and monkeypox) by targeting the viral VP37 protein, blocking the formation and release of enveloped virions from infected cells, and preventing virus dissemination within the host. It is approved for smallpox and investigational for other orthopoxvirus infections[1][2][5][7]. - **Sucroferric oxyhydroxide** is an iron-based, non-calcium, non-aluminum phosphate binder used to lower serum phosphate levels in patients with chronic kidney disease on dialysis. It binds phosphate in the gastrointestinal tract, reducing absorption and thus serum phosphate. There is no evidence of this specific combination drug being approved, marketed, or under clinical investigation as a fixed product as of September 2025. The entry likely refers to co-administration rather than a single pharmaceutical product.

Other names

sucroferric oxyhydroxide